We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals
XENE

103 hedge funds and large institutions have $671M invested in Xenon Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 29 increasing their positions, 31 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

493% more call options, than puts

Call options by funds: $3.86M | Put options by funds: $652K

300% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 4

200% more funds holding in top 10

Funds holding in top 10: 2 → 6 (+4)

14% more capital invested

Capital invested by funds: $590M → $671M (+$80.7M)

13% more funds holding

Funds holding: 91 → 103 (+12)

0.2% less ownership

Funds ownership: 82.14% → 81.94% (-0.2%)

6% less repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 31

Holders
103
Holders Change
+12
Holders Change %
+13.19%
% of All Funds
1.79%
Holding in Top 10
6
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+200%
% of All Funds
0.1%
New
16
Increased
29
Reduced
31
Closed
4
Calls
$3.86M
Puts
$652K
Net Calls
+$3.21M
Net Calls Change
+$126K

Top Buyers

1
PA
Perceptive Advisors
New York
+$21.5M
2
BC
Boxer Capital
California
+$15.8M
3
Citadel Advisors
Citadel Advisors
Florida
+$15.1M
4
CS
Candriam SCA
Luxembourg
+$13.2M
5
MWNA
Marshall Wace North America
New York
+$7.58M

Top Sellers

1
BI
BVF Inc
California
-$35.2M
2
O
OrbiMed
New York
-$21.5M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$18.9M
4
SCM
Soleus Capital Management
Connecticut
-$8.74M
5
California Public Employees Retirement System
California Public Employees Retirement System
California
-$1.25M
Name Holding Trade Value Shares
Change 		Change in
Stake
MWNA
26
Marshall Wace North America
New York
$7.66M +$7.58M +411,259 New
DCM
27
DAFNA Capital Management
California
$7.57M – – –
PHP
28
Parkman Healthcare Partners
Connecticut
$7.47M +$494K +26,812 +7%
Lord, Abbett & Co
29
Lord, Abbett & Co
New Jersey
$7.16M -$623K -33,825 -8%
CC
30
Commodore Capital
New York
$6.08M +$460K +24,944 +8%
UBS AM
31
UBS AM
Illinois
$5.94M -$288K -15,651 -5%
Millennium Management
32
Millennium Management
New York
$5.62M -$759K -41,151 -12%
SCM
33
Soleus Capital Management
Connecticut
$4.35M -$8.74M -474,420 -67%
NFGH
34
Nan Fung Group Holdings
Hong Kong
$3.69M +$3.65M +197,880 New
AGA
35
Altrinsic Global Advisors
Connecticut
$3.17M – – –
TCM
36
Tekla Capital Management
Massachusetts
$3.15M +$57.7K +3,132 +2%
D.E. Shaw & Co
37
D.E. Shaw & Co
New York
$3.06M -$201K -10,924 -6%
ACM
38
Altium Capital Management
New York
$2.89M +$2.86M +155,000 New
Goldman Sachs
39
Goldman Sachs
New York
$2.83M +$313K +16,999 +13%
DMK
40
David M. Knott
$2.62M -$65.4K -3,550 -2%
State Street
41
State Street
Massachusetts
$2.43M +$599K +32,507 +33%
GPCM
42
Granite Point Capital Management
Massachusetts
$2.05M +$737K +40,000 +57%
Vanguard Group
43
Vanguard Group
Pennsylvania
$1.93M -$61.9K -3,359 -3%
SSA
44
Schonfeld Strategic Advisors
New York
$1.8M +$243K +13,200 +16%
BFM
45
Boothbay Fund Management
New York
$1.78M +$91.1K +4,941 +5%
Bank of Montreal
46
Bank of Montreal
Ontario, Canada
$1.62M +$453K +24,588 +39%
Two Sigma Investments
47
Two Sigma Investments
New York
$1.59M +$157K +8,512 +11%
GIM
48
Granahan Investment Management
Massachusetts
$1.55M +$2.97K +161 +0.2%
Two Sigma Advisers
49
Two Sigma Advisers
New York
$1.54M -$109K -5,900 -7%
Swiss National Bank
50
Swiss National Bank
Switzerland
$1.15M -$38.7K -2,100 -3%
1
2
3 4 5

XENE Hedge Fund Activity: Q2 2021 in Review

103 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q2 2021, worth a combined $671M — up 14% from $590M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new XENE positions and 4 closed out — a net gain of 12 holders — while 29 added to existing stakes and 31 trimmed.

The largest buyer was Perceptive Advisors, adding an estimated $21.5M. The largest seller was BVF Inc, cutting an estimated $35.2M.

  • 103 institutional investors held Xenon Pharmaceuticals (XENE) as of Q2 2021, up from 91 in Q1 2021.
  • Funds reported $671M of Xenon Pharmaceuticals stock for Q2 2021, up 14% quarter-over-quarter.
  • 16 funds opened new Xenon Pharmaceuticals positions in Q2 2021 and 4 closed out, a net change of +12 holders.
  • The largest Xenon Pharmaceuticals buyer in Q2 2021 was Perceptive Advisors, an estimated $21.5M added.
  • The largest Xenon Pharmaceuticals seller in Q2 2021 was BVF Inc, an estimated $35.2M sold.

Based on aggregated 13F filings for Q2 2021.